---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-112166"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T07:14:56.799212+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq Panel grants TransCode continued listing extension to Jan 22, 2024

## Summary
- Company must provide update on meeting stockholders' equity requirement by Nov 14, 2023 after Q3 10-Q filing.
- By Jan 22, 2024, must demonstrate long-term compliance with Nasdaq's $2.5M stockholders' equity rule.
- Panel cannot extend listing beyond Jan 22 if compliance not achieved; conditions may be reconsidered.
- Company must promptly notify Nasdaq of any events that could affect compliance during exception period.
- Previously received delisting determination after Staff rejected compliance plan; hearing held Oct 5, 2023.

## SEC filing metadata
- accession: 0001104659-23-112166
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923112166/0001104659-23-112166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923112166/tm2329299d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-112166
- JSON: https://secwatch.observer/filing/0001104659-23-112166.json
- Plain text: https://secwatch.observer/filing/0001104659-23-112166.txt

## Key facts
- Listing & Compliance Notices
  Transcode Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5815(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5815(a)(2)
  source text: October 26, 2023, the Company received written notice from Nasdaq (the “October Notification Letter”) that the Panel had granted the Company an exception from compliance with the Stockholders Equity Requirement and extension of continued listing until January 22, 2024, subject to the following: 1. On or before November 14, 2023, the Company shall provide a detailed update to the Panel regarding its meeting the Stockholders’ Equity Requirement; and 2. On or before January 22, 2024, the Company shall provide an update to the Panel on how it demonstrates long-term compliance with the Stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923112166/0001104659-23-112166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.